Research Coverage on Small and Micro-Cap Companies, Zacks Small Cap Research

Zacks Small Cap Research

Research Coverage on Small and Micro-Cap Companies

Zacks Small Cap Research provides research coverage on small- and micro-cap companies that are “under-followed” or “under-valued” by Wall Street. We produce high quality equity research for the institutional and retail investor on microcap firms we believe are well positioned for future growth. The Zacks SCR analyst team has an average of 20 years of experience in investment research. We conduct significant due diligence in an effort to maintain the highest quality small-cap universe.

Equity Bottom-Up

<ul><li>On May 10, 2024, Virios Therapeutics, Inc. (VIRI) announced financial results for the first quarter of 2024 and provided a business update.</li><li>The company announced that the Phase 2 clinical trial of IMC-2 (valacycovir+celecoxib) has reached 50% enrollment and we anticipate topline results from the trial in the second half of 2024.</li><li>Earlier this year, Virios announced that it had reached alignment with the U.S. Food and Drug Administration (FDA) that would allow the company to use fatigue as the primary endpoint and orthostatic intolerance as a key secondary endpoint in future trials of IMC-2 for the treatment of Long COVID. The results of the ongoing Phase 2 trial of IMC-2 will help to guide the final design of a Phase 2b trial.</li></ul>

On May 10, 2024, Virios Therapeutics, Inc. (VIRI) announced financial results for the first quarter of 2024 and provided a business update.The company announced that the Phase 2 clinical trial of IMC-2 (valacycovir+celecoxib) has reached 50% enrollment and we anticipate topline results from the trial in the second half of 2024.Earlier this year, Virios announced that it had reached alignment with the U.S. Food and Drug Administration (FDA) that would allow the company to use fatigue as the primary endpoint and orthostatic intolerance as a key secondary endpoint in future trials of IMC-2 for the treatment of Long COVID. The results of the ongoing Phase 2 trial of IMC-2 will help to guide the final design of a Phase 2b trial.

VIRI: Results for Phase 2 Long COVID Trial Expected in 2H24 

United States

Aravive, Inc. operates as a biotechnology company. The Company develops therapeutic proteins for the treatment of metabolic diseases and endocrine disorders. Aravive serves patients in the United States.

Trevena, Inc. develops pharmaceutical products. The Company offers discovery and development of agents targeting G-protein coupled receptors and therapies and drugs that treat acute heart failure, acute chronic pain, and depression. Trevena serves customers throughout the United States.

Sorrento Therapeutics, Inc. is a biopharmaceutical company. The Company researches human therapeutic antibodies for the treatment of cancer, inflammation, metabolic, and infectious diseases.

Organovo Holdings, Inc. operates as a biology company. The Company focuses on bio-printing technology and creating tissues for research and medical applications.

Tonix Pharmaceuticals Holding Corp. is a pharmaceutical company that develops therapies for disorders of the central nervous system ("CNS").  The Company develops therapies for disorders that include fibromyalgia syndrome ("FM") and post-traumatic stress disorder ("PTSD"),

Aptinyx Inc. operates as a bio-pharmaceutical company. The Company focuses on discovery, development, and commercialization of novel, proprietary, and synthetic small molecules for the treatment of brain and nervous system disorders. Aptinyx serves patients in the United States.

Ensysce Biosciences, Inc. operates as a clinical stage biotech company. The Company focuses on stemming the prescription drug abuse epidemic. Ensysce Biosciences serves customers worldwide.

Calithera Biosciences, Inc. provides pharmaceutical products. The Company is focused on discovering and developing novel small molecule drugs against tumor metabolism and immunology for the treatment of cancer. Calithera Biosciences serves patrients in the United States.

Bellicum Pharmaceuticals, Inc. operates as a biopharmaceutical company. The Company focuses on discovering and developing novel cellular immunotherapies for cancer, tumors, and blood diseases. Bellicum Pharmaceuticals serves patients in the United States.

Navidea Biopharmaceuticals Inc. is a biopharmaceutical company. The Company is focused on the development and commercialization of precision radiopharmaceutical diagnostics for diseases such as cancer.

Biosino Bio-Technology & Science, Inc. is a biotechnology company.  The Company develops, manufactures, and markets protein-based in-vitro diagnostic reagents and biochemical drugs.  The Company's diagnostic reagents help diagnose cardiac, helatic, diabetes, inflammation/immunology, and pancreatic related diseases.

Patrys Limited develops therapies for the capture, production, and development of natural human antibodies as therapies for cancer and other diseases.

Algorae Pharmaceuticals Limited operates as a clinical-stage pharmaceutical company. The Company focuses on research and development programs to accelerate patient access to novel drugs and therapies using the latest technologies and scientific innovations. Algorae Pharmaceuticals offers its services worldwide.

Bionomics Limited operates as a biotechnology company, which specializes in the genetics field.  The Company, which is affiliated with a number of research institutions, seeks to develop a variety of genomic, genetic, molecular and cell biology techniques, which they believe will help demonstrate the onset and progression of diseases like epilepsy and breast cancer.

Bioxyne  Limited operates as a biotechnology company.  The Company specializes in the research, development and commercialization of diseases related to chronic obstructive pulmonary disease(COPD).

DorsaVi Ltd. develops and sells wireless sensor movement monitoring systems. The Company's technology is used by the to monitor workplace and sports related injury and pain.

Regeneus Ltd is a regenerative medicine company focused on using the regenerative capacities of adipose-derived cells to develop innovative cell therapies for humans and animals.

Oncimmune Limited develops and commercializes products for the detection of cancerous. It develops autoantibody assay technologies that have the potential to early detection a range of solid cancer tumor types. It offers EarlyCDT-Lung, a blood test that is ordered by a doctor to aid in the risk assessment and early detection of lung cancer in high-risk patients and to stratify indeterminate pulmonary nodules for the risk of malignancy. The company is based in Nottingham, the United Kingdom.

Celyad Oncology SA is a bio-pharmaceutical company. The Company specialized in CAR-T cell therapy, that is developing landmark technologies aimed at treating severe diseases with poor prognosis, such as cancer. Celyad Oncology serves customers worldwide.

Hybrigenics S.A. is a biotechnology and pharmaceutical company. The Company develops therapeutics against cancer as well as develops platforms to identify, validate and inhibit protein interactions.

Virios Therapeutics, Inc. operates as a biotechnology company. The Company develops novel antiviral therapies to treat diseases associated with a viral triggered abnormal immune response. Virios Therapeutics serves patients in the United States.

Price Gauge
52-week Range	0.00 - 0.00
Market Cap (USDm)	0.00
P/E	0.00
Dividend (Yield)	0.00

Virios Therapeutics (VIRI US)

VIRI: Results for Phase 2 Long COVID Trial Expected in 2H24

On May 10, 2024, Virios Therapeutics, Inc. (VIRI) announced financial results for the first quarter of 2024 and provided a business update. The...

Zacks Small Cap Research

Price Gauge

52-week Range

Market Cap (USDm)

P/E

Dividend (Yield)